Study of Mirogabalin for Central Neuropathic Pain

• Status: Completed
• Trial end date: 2020-12-28
• Target enrollment: 0
• Participant gender: All

Summary

Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Co., Ltd.

Criteria

Inclusion Criteria:

• Spinal cord injury (SCI) due to trauma

• American Spinal Injury Association impairment scale A, B, C, or D

Exclusion Criteria:

• Other severe pain at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI

• Neurologic disorders at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI

• Major psychiatric disorders within 1 year prior to screening